Japan: DOE and cross-border infringement of a biologics process patent
The Tokyo District Court judgment on patent infringement and question of territoriality is game-changing, says Takanori Abe of Abe & Partners.
- Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox 27-05-2022
- Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing 08-03-2022
- A new drug pricing system reform proposal in Japan 17-08-2021
- Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020
Latest abe & partners news
Abe & Partners makes two promotions
23-01-2018
Japan-based Abe & Partners has promoted Michiko Kinoshita as partner and Tomohiro Kazama as counsel.
